Implantable Recorders Wearable Monitors
Customize your policy alerts
Sign up for sierra health and life Policy 2026T0489JJ alerts
Get alerted when Policy 2026T0489JJ changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity criteria for implantable loop recorders (ILRs) and coverage stance for wearable cardiac self-monitoring devices for UnitedHealthcare Commercial and Individual Exchange plans; excludes individuals <18 years. Also addresses replacement of ILRs and describes devices considered convenience items (consumer-grade/self-monitoring).
Policy does not apply to individuals < 18 years of age.
Revised circumstances for which Implantable Loop Recorders are proven and medically necessary when noninvasive cardiac event recording is contraindicated or nondiagnostic after at least 2 weeks of monitoring.
Supporting Information, Clinical Evidence and References sections updated to reflect current information.
Coverage Summary
Policy 2026T0489JJ (Implantable Loop Recorders and Wearable Heart Rhythm Monitors) is a UnitedHealthcare Commercial and Individual Exchange coverage criteria effective May 1, 2026 and is CURRENT. The policy defines medical necessity criteria for implantable loop recorders (ILRs) for specified arrhythmia indications and for replacement of ILRs, excludes individuals under 18 years of age, and states a mixed coverage stance: ILRs are covered when criteria are met while consumer-grade cardiac self-monitoring devices (wearables) are not covered as convenience items.
Medically Necessary Criteria
Medically Necessary Indications for Implantable Loop Recorder
Implantable Loop Recorders are proven and medically necessary when noninvasive cardiac event recording is contraindicated or has yielded nondiagnostic results after at least 2 weeks of monitoring in one or more of the following circumstances:
ANY of the following
- Suspected paroxysmal atrial fibrillation in the setting of a cryptogenic stroke or another documented systemic thromboembolic event
- Suspected or known ventricular arrhythmia
- High risk for arrhythmia secondary to structural or infiltrative heart disease (examples: aortic stenosis, hypertrophic cardiomyopathy, cardiac sarcoidosis, congenital heart disease, family history, dilated ischemic or nonischemic cardiomyopathy, or use of medications known to cause malignant arrhythmias such as those prolonging the QT interval)
- Recurrent or unexplained infrequent syncope after modification of potentially syncope-causing medications or associated with autonomic dysfunction
- Post-cavotricuspid isthmus (CTI) ablation for typical atrial flutter if the individual is not on long-term anticoagulation and is at high thromboembolic risk (e.g., CHA2DS2-VASc ≥ 2 or HATCH score of at least 2)CHA2DS2-VASc ≥ 2; HATCH ≥ 2
- Atrial fibrillation detected during an acute medical illness or following surgery, particularly after noncardiac procedures and in individuals with stroke risk factors (e.g., CHA2DS2-VASc ≥ 2)CHA2DS2-VASc ≥ 2
- Abnormal tests such as electrophysiology study or tilt table testing
Replacement of Implantable Loop Recorder
Replacement is considered medically necessary when ALL of the following are met:
ALL of the following
- Individual continues to meet all initial criteria for insertion described above
- Existing device is beyond its useful lifespan, irreparable, or no longer operating
Revised Coverage Rationale (summary of changed indications)
Implantable Loop Recorders are proven and medically necessary when noninvasive cardiac event recording is contraindicated or nondiagnostic after adequate monitoring; added specific circumstances:
ALL of the following
- Noninvasive cardiac event recording is contraindicated or has yielded nondiagnostic results after at least 2 weeks of monitoringAt least 2 weeks
AND ONE OF
- Post-cavotricuspid isthmus (CTI) ablation for typical atrial flutter if the individual is not on long-term anticoagulation and is at high thromboembolic risk (example risk criteria provided)CHA2DS2-VASc ≥ 2; HATCH ≥ 2
- Atrial fibrillation detected during an acute medical illness or following surgery, particularly after noncardiac procedures, in individuals with stroke risk factors (e.g., CHA2DS2-VASc ≥ 2)CHA2DS2-VASc ≥ 2
Age Exclusion
Not Medically Necessary / Convenience Items
Not Medically Necessary / Convenience Items
Wearable heart rhythm monitors or Cardiac Self-Monitoring Devices commercially available to the general public and purchased for home use are not medically necessary:
ANY of the following
- Self-monitoring device that includes an electrocardiographic monitor combined with a personal electronic device such as a cellular telephone or watch
- Hardware or software required for downloading electrocardiographic data to a device such as a personal computer, tablet, or smartphone
Wearable consumer-grade heart rhythm monitoring devices and related software are considered convenience items with insufficient evidence of clinical efficacy and are designated not medically necessary / not covered under this policy. The policy cites lack of quality research demonstrating safety and effectiveness for identifying arrhythmias as the rationale for excluding these devices from coverage.
Codes and Billing
| 0650T | Programming device evaluation (remote) of subcutaneous cardiac rhythm monitor system, with iterative adjustment... |
| 33285 | Insertion, subcutaneous cardiac rhythm monitor, including programming |
| 33286 | Removal, subcutaneous cardiac rhythm monitor |
| 93285 | Programming device evaluation (in person) with iterative adjustment...; subcutaneous cardiac rhythm monitor system |
| 93291 | Interrogation device evaluation (in person) with analysis, review and report...; subcutaneous cardiac rhythm monitor system, including heart rhythm derived data analysis |
| 93297 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system... |
| 93298 | Interrogation device evaluation(s), (remote) up to 30 days; subcutaneous cardiac rhythm monitor system... |
| FDA product codes DSI, MXD, DXH | Ambulatory electrocardiography devices, cardiac telemetry, implantable loop recorders (informational reference) |
| FDA product codes DXH, DPS, QDA | Cardiac self-monitoring devices classification reference |
Provider Actions / Prior Authorization & Documentation
Prior Authorization May Be Required
Coverage determination for implantable loop recorders (ILRs) and related services may require prior authorization. Submission of medical records is necessary to demonstrate that the individual meets the policy criteria (including prior nondiagnostic external monitoring or a contraindication to such monitoring) and that the clinical indication aligns with the policy's listed indications.
- Submit documentation of at least 2 weeks of nondiagnostic external ambulatory cardiac monitoring (or documentation that external monitoring is contraindicated or not feasible).
- Provide clinical documentation demonstrating one of the policy-listed indications for ILR insertion (e.g., suspected paroxysmal atrial fibrillation after cryptogenic stroke, unexplained infrequent syncope, suspected/known ventricular arrhythmia, high-risk structural/infiltrative heart disease, post‑CTI ablation in select individuals, abnormal electrophysiology or tilt table testing).
- Include relevant prior test reports, clinician notes, and rationale for why ILR is indicated over continued external monitoring.
- Prior authorization review does not guarantee coverage; final coverage is based on member-specific benefits and completed medical record review.
Documentation Required
Medical records must support the request for an ILR. Ensure records clearly document age, prior nondiagnostic monitoring or a contraindication to such monitoring, and the specific clinical indication that meets policy criteria.
- Do not apply this policy to individuals under 18 years of age — do not submit requests for members < 18.
- Ensure the member's age is clearly documented in the medical record.
- Document at least 2 weeks of nondiagnostic external cardiac monitoring (with dates and results) OR a clear contraindication to external monitoring.
- Include clinical notes that specify which policy indication is met and supporting diagnostic test results (e.g., ECGs, electrophysiology study, tilt table test, stroke workup).
Background, Evidence, and Definitions
ILRs are indicated because they provide extended continuous monitoring tailored to the frequency of symptoms and have substantially higher atrial fibrillation detection rates than conventional monitoring (meta-analysis showing ~three-fold increased AF detection with ILR). The policy notes ILRs are useful for infrequent palpitations, syncope, cryptogenic stroke evaluation, post‑ablation surveillance and other high‑risk scenarios. By contrast, consumer-grade wearable devices are described as convenience items with insufficient evidence of clinical efficacy and therefore are not covered.
| Study / Source | Key finding |
|---|---|
| Janmohamadi et al. (2025) | Meta-analysis: ILR associated with higher AF detection (HR 3.13; 95% CI 1.97–4.97) vs controls; no significant reduction in embolic events or mortality |
| Abideen Asad et al. (2024) | Systematic review of RCTs: ILR increased AF detection and anticoagulation starts; uncertain stroke prevention benefit (RR 0.75 overall; no significant benefit in prior-stroke subgroup) |
| Jiang et al. (2022) | Meta-analysis in cryptogenic stroke: ILR pooled AF rate rose from 4.9% at 1 month to 38.4% at 36 months; MCOT detects more AF at 1 month |
| Multiple systematic reviews / meta-analyses | Consistent finding: ILRs yield substantially higher AF detection and higher diagnostic yield for unexplained syncope and post-op AF recurrence vs conventional monitoring; noninvasive MCOT may detect substantial AF within 1 month |
| Diagnostic yield subgroup (Apple Heart / ECG patch data) | Among smartwatch-notified participants who returned ECG patches, AF present in 153 (34%); yield 35% for ≥65 yrs and 18% for <40 yrs |
| Participant survey results (Apple Heart Study) | Of 1,376 responders after notification: 57% contacted provider, 28% prescribed new medication, 33% referred to specialist, 36% recommended additional testing; 44% reported new AF diagnosis on end-study survey |
| Guideline consensus (ACC/AHA/ESC/AHA/ASA/etc.) | Multiple guidelines support extended monitoring/ILR for cryptogenic stroke, unexplained syncope, post-ablation surveillance, HCM and other high-risk populations; recommend ≥14 days (or ILR for selected high-risk) and consider ILR when noninvasive monitoring nondiagnostic |
| Attanasio et al. (FLUTFIB, 2024) | Prospective ILR study after CTI ablation: 77% developed AF over median 24 months, often asymptomatic; findings support post-ablation surveillance considerations |
| Policy coverage rationale / thresholds | Policy: ILRs medically necessary when noninvasive recording contraindicated or nondiagnostic after ≥2 weeks and for listed indications (eg, cryptogenic stroke, ventricular arrhythmia, post-CTI ablation with CHA2DS2-VASc ≥2) |
Revision History
Age exclusion language added to Coverage Rationale: Policy does not apply to individuals < 18 years of age. (Material change)
Revised coverage rationale to add specific circumstances in which Implantable Loop Recorders are proven and medically necessary when noninvasive cardiac event recording is contraindicated or nondiagnostic after at least 2 weeks of monitoring, including post-cavotricuspid isthmus (CTI) ablation for typical atrial flutter if not on long-term anticoagulation and at high thromboembolic risk (e.g., CHA2DS2-VASc ≥ 2 or HATCH ≥ 2), and atrial fibrillation detected during acute medical illness or following surgery, particularly after noncardiac procedures in individuals with stroke risk factors (e.g., CHA2DS2-VASc ≥ 2). (Material change)
Supporting Information, Clinical Evidence and References sections updated to reflect current information; previous policy version 2026T0489II archived.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.